The Feasibility and Tolerability of Medium Chain Triglycerides in Women with a Catamenial Seizure Pattern on the Modified Atkins Diet

• Main Authors: Elizabeth A. Felton, Bobbie J. Henry-Barron, Amanda K. Jan, Abigail Shegelman, Kelly Faltersack, Diane Vizthum, Mackenzie C. Cervenka
• Format: Article
• Language: English
• Published: MDPI AG 2021-06-01
• Series: Nutrients
• Subjects: epilepsy; seizure; ketogenic diet therapy; catamenial; medium chain triglyceride (MCT)
• Online Access: https://www.mdpi.com/2072-6643/13/7/2261

Ketogenic diet therapy (KDT), particularly modified Atkins diet (MAD), is increasingly recognized as a treatment for adults with epilepsy. Women with epilepsy (WWE) comprise 50% of people with epilepsy and approximately one in three have catamenial epilepsy. The purpose of this study was to determine whether adding a medium chain triglyceride emulsion to MAD to target catamenial seizures was feasible and well-tolerated. This was a prospective two-center study of pre-menopausal WWE with a catamenial seizure pattern on MAD. After a 1-month baseline interval with no changes in treatment, participants consumed betaquik^® (Vitaflo International Ltd.) for 10 days each menstrual cycle starting 2 days prior to and encompassing the primary catamenial seizure pattern for five cycles. Participants recorded seizures, ketones, and menses, and completed surveys measuring tolerability. Sixteen women aged 20–50 years (mean 32) were enrolled and 13 (81.2%) completed the study. There was 100% adherence for consuming betaquik^® in the women who completed the study and overall intervention adherence rate including the participants that dropped out was 81.2%. The most common side effects attributed to MAD alone prior to starting betaquik^® were constipation and nausea, whereas abdominal pain, diarrhea, and nausea were reported after adding betaquik^®. The high adherence rate and acceptable tolerability of betaquik^® shows feasibility for future studies evaluating KDT-based treatments for catamenial seizures.